Yun et al. (2020) demonstrated that repotrectinib exhibited potent antitumor activity in the CNS with efficient BBB penetrating properties in ROS1+ patient-derived xenograft (PDX) mouse models with brain metastases of NSCLC [12]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.